Literature DB >> 32199027

Unexpected overdose blood concentration of tacrolimus: Keep in mind the role of inflammation.

Edouard Bonneville1, Elodie Gautier-Veyret1,2, Cordelia Ihl3, Marie-Noelle Hilleret4, Magalie Baudrant3, Xavier Fonrose1, Françoise Stanke-Labesque1,2.   

Abstract

Tacrolimus is the cornerstone of the therapeutic immunosuppressive strategy in liver transplantation. The inter-individual and intra-individual variability of its trough blood concentrations is a surrogated biomarker of allograft rejection. Here we described two cases of patients with liver transplant who exhibited increases of tacrolimus blood trough concentration adjusted on the dose while experiencing acute inflammatory episodes. These case reports highlight the inhibitory effect of acute inflammation on tacrolimus metabolism and show that it accounts for the longitudinal intra-individual variability of tacrolimus blood concentrations, beyond drug-drug interaction and observance.
© 2020 The British Pharmacological Society.

Entities:  

Keywords:  clinical pharmacology; drug safety; inflammation; therapeutic drug monitoring

Mesh:

Substances:

Year:  2020        PMID: 32199027      PMCID: PMC7444753          DOI: 10.1111/bcp.14292

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  High Intrapatient Variability of Tacrolimus Exposure in the Early Period After Liver Transplantation Is Associated With Poorer Outcomes.

Authors:  Michel Rayar; Camille Tron; Caroline Jézéquel; Jean Marie Beaurepaire; Antoine Petitcollin; Pauline Houssel-Debry; Christophe Camus; Marie Clémence Verdier; Ammar Dehlawi; Mohamed Lakéhal; Véronique Desfourneaux; Bernard Meunier; Laurent Sulpice; Eric Bellissant; Karim Boudjema; Florian Lemaitre
Journal:  Transplantation       Date:  2018-03       Impact factor: 4.939

Review 2.  Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.

Authors:  Rashmi R Shah; Robert L Smith
Journal:  Drug Metab Dispos       Date:  2014-12-17       Impact factor: 3.922

3.  Unexpected overdose blood concentration of tacrolimus: Keep in mind the role of inflammation.

Authors:  Edouard Bonneville; Elodie Gautier-Veyret; Cordelia Ihl; Marie-Noelle Hilleret; Magalie Baudrant; Xavier Fonrose; Françoise Stanke-Labesque
Journal:  Br J Clin Pharmacol       Date:  2020-04-20       Impact factor: 4.335

4.  Systemic Inflammation Complicates the Interpretation of Therapeutic Drug Monitoring of Risperidone.

Authors:  Arne Helland; Simone Habib; Line Ulvestad; Olav Spigset
Journal:  J Clin Psychopharmacol       Date:  2018-06       Impact factor: 3.153

5.  Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.

Authors:  Mercè Brunet; Teun van Gelder; Anders Åsberg; Vincent Haufroid; Dennis A Hesselink; Loralie Langman; Florian Lemaitre; Pierre Marquet; Christoph Seger; Maria Shipkova; Alexander Vinks; Pierre Wallemacq; Eberhard Wieland; Jean Baptiste Woillard; Markus J Barten; Klemens Budde; Helena Colom; Maja-Theresa Dieterlen; Laure Elens; Kamisha L Johnson-Davis; Paweł K Kunicki; Iain MacPhee; Satohiro Masuda; Binu S Mathew; Olga Millán; Tomoyuki Mizuno; Dirk-Jan A R Moes; Caroline Monchaud; Ofelia Noceti; Tomasz Pawinski; Nicolas Picard; Ron van Schaik; Claudia Sommerer; Nils Tore Vethe; Brenda de Winter; Uwe Christians; Stein Bergan
Journal:  Ther Drug Monit       Date:  2019-06       Impact factor: 3.681

6.  The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration-Dose Ratio on Death-censored Graft Survival.

Authors:  Thomas Jouve; Xavier Fonrose; Johan Noble; Benedicte Janbon; Gaelle Fiard; Paolo Malvezzi; Françoise Stanke-Labesque; Lionel Rostaing
Journal:  Transplantation       Date:  2020-06       Impact factor: 4.939

7.  Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein.

Authors:  Sachiko Maezono; Koh-ichi Sugimoto; Koh-ichi Sakamoto; Masami Ohmori; Shuji Hishikawa; Koichi Mizuta; Hideo Kawarasaki; Yoshiteru Watanabe; Akio Fujimura
Journal:  Pediatr Transplant       Date:  2005-06

Review 8.  Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation.

Authors:  M A Sikma; E M van Maarseveen; E A van de Graaf; J H Kirkels; M C Verhaar; D W Donker; J Kesecioglu; J Meulenbelt
Journal:  Am J Transplant       Date:  2015-06-04       Impact factor: 8.086

9.  Toxic rise of clozapine plasma concentrations in relation to inflammation.

Authors:  Marie Jeanne Haack; M L F J Bak; Rob Beurskens; Michael Maes; L M L Stolk; Philippe A E G Delespaul
Journal:  Eur Neuropsychopharmacol       Date:  2003-10       Impact factor: 4.600

10.  Inflammation is a potential risk factor of voriconazole overdose in hematological patients.

Authors:  Elodie Gautier-Veyret; Aurélie Truffot; Sébastien Bailly; Xavier Fonrose; Anne Thiebaut-Bertrand; Julia Tonini; Jean-Yves Cahn; Françoise Stanke-Labesque
Journal:  Fundam Clin Pharmacol       Date:  2018-12-07       Impact factor: 2.748

  10 in total
  4 in total

1.  Unexpected overdose blood concentration of tacrolimus: Keep in mind the role of inflammation.

Authors:  Edouard Bonneville; Elodie Gautier-Veyret; Cordelia Ihl; Marie-Noelle Hilleret; Magalie Baudrant; Xavier Fonrose; Françoise Stanke-Labesque
Journal:  Br J Clin Pharmacol       Date:  2020-04-20       Impact factor: 4.335

2.  Association of intraindividual tacrolimus variability with de novo donor-specific HLA antibody development and allograft rejection in pediatric kidney transplant recipients with low immunological risk.

Authors:  Maral Baghai Arassi; Laura Gauche; Jeremy Schmidt; Britta Höcker; Susanne Rieger; Caner Süsal; Burkhard Tönshoff; Alexander Fichtner
Journal:  Pediatr Nephrol       Date:  2022-02-15       Impact factor: 3.651

Review 3.  Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.

Authors:  Nicolas Venisse; Gilles Peytavin; Stephane Bouchet; Marie-Claude Gagnieu; Rodolphe Garraffo; Romain Guilhaumou; Caroline Solas
Journal:  Antiviral Res       Date:  2020-07-10       Impact factor: 5.970

Review 4.  Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment.

Authors:  Françoise Stanke-Labesque; Elodie Gautier-Veyret; Stephanie Chhun; Romain Guilhaumou
Journal:  Pharmacol Ther       Date:  2020-07-11       Impact factor: 12.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.